Research validates efficacy of nanoparticle drug-delivery approach for brain disorders

Healthcare

Over the past few decades, research has led to promising developments to understand causes of neurodegenerative diseases. With clinical trials, researchers have discovered biological pathways that develop into neurodegenerative diseases and have developed molecular agents to target them. However, the progression of these findings to translate into clinically approved treatments has been at a slower rate. To some extent, this is because of the challenges scientists encounter to deliver therapeutics across the blood-brain barrier and into the brain.

Thus, in order to assist successful administration of therapeutic agents into the brain, a team of bioengineers and physicians at a few medical centers in parts of the U.S. have created a nanoparticle platform. It features therapeutically effective delivery of enveloped agents. The efficacy of the platform comes to the fore via mice model with a physically damaged or intact blood-brain barrier.

Clinical Trials on Mouse Model show merits of approach

In fact, the examination of a mouse model with traumatic brain injury led to some rewarding findings. During examination, researchers observed some interesting facts, first, the delivery system showed accumulation in brain to be three times more than conventional methods of delivery, and was therapeutically more effective. With such results, the platform opens possibilities for the treatment of numerous neurological disorders. The findings of the research is published in Science Advances.

Meanwhile, previously developed therapeutics for traumatic brain injury work on a different base. The short window of time, after a physical injury to the head, and when the blood-brain brainer is temporarily dysfunctional, is what previously developed therapeutics work on. However, after repair of blood-brain brainer within a few weeks, there is deficit of tools for effective drug delivery.

β€œAnd, to deliver both small and large molecule therapeutic agents across the blood-brain brainer is very difficult,” said one of the associates.

Leave a Reply